Last reviewed · How we verify
NCT03898635
Retrospective Real-word Study of Linezolid for the Treatment of Tuberculous Meningitis
trial testing Linezolid in Tuberculous Meningitis in 150 participants. Status unknown.
1 May 2019
Quick facts
| Lead sponsor | Huashan Hospital |
|---|---|
| Status | Status unknown |
| Study type | OBSERVATIONAL |
| Enrollment | 150 |
| Start date | 1 January 2018 |
| Primary completion | 1 May 2019 |
| Estimated completion | 1 June 2019 |
| Sites | 1 location across China |
Drugs / interventions tested
- Linezolid — full drug profile →
Conditions studied
- Tuberculous Meningitis — all drugs for Tuberculous Meningitis →
Sponsor
Huashan Hospital
Who can join
18 and older, any sex, with Tuberculous Meningitis. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Tuberculous meningitis (TBM) is the most serious form of Mycobacterium tuberculosis infection, causing mortality and disability in more than half of the patients. Current standard treatment for TBM is based on those developed to treat pulmonary tuberculosis, which does not take into account the differential ability of anti-tuberculosis drugs to penetrate the brain. With both good central nervous system penetrance and anti-tuberculosis efficacy that have been demonstrated in drug-resistant tuberculosis, linezolid may be a promising antimicrobial in TBM treatment. The purpose of this study is to evaluate the effectiveness of linezolid in the treatment of TBM.
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
The current global situation for tuberculous meningitis: epidemiology, diagnostics, treatment and outcomes.
Seddon JA, Tugume L, Solomons R, Prasad K, et al · · 2019 · cited 86× · PMID 32118118 · DOI 10.12688/wellcomeopenres.15535.1
Verify or expand the search:
- PubMed search for NCT03898635
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Linezolid
Trials testing the same drug.
- NCT06192160 — Trial of Novel Regimens for the Treatment of Pulmonary Tuberculosis · Phase 2 · recruiting
- NCT06444802 — Model-informed Precision Dosing for Linezolid · Phase 3 · not yet recruiting
- NCT06081361 — Innovating Shorter, All- Oral, Precised, Individualized Treatment Regimen for Rifampicin Resistant Tuberculosis：Contezol · Phase 3 · active not recruiting
- NCT06126263 — Adjunctive Clindamycin Versus Linezolid for β-lactam Treated Patients With Invasive Group A Streptococcal Infections · unknown
- NCT05813951 — Efficacy and Safety of Continuous Versus Intermittent Linezolid Infusion in Critically Ill Patients With Septic Shock · NA · unknown
Other recruiting trials for Tuberculous Meningitis
Currently open trials in the same condition.
- NCT05383742 — Trial of a Six-Month Regimen of High-Dose Rifampicin, High-Dose Isoniazid, Linezolid, and Pyrazinamide Versus a Standard · Phase 2 · recruiting
Other Huashan Hospital trials
Trials by the same sponsor.
- NCT07469735 — Vorasidenib Guided by AGX PET in Recurrent/Low-grade Glioma · NA · not yet recruiting
- NCT07364487 — This is an Open-Label Study to Assess the Safety and Efficacy of GC012F in Patients With Multiple Sclerosis · EARLY_PHASE1 · withdrawn
- NCT07369830 — The Impact of Probiotic Intervention on the Gut Microbiota and Bowel Function · NA · recruiting
- NCT07185373 — Orelabrutinib Combined With Teniposide, Rituximab and Methotrexate for Newly Diagnosed PCNSL · Phase 2, PHASE3 · not yet recruiting
- NCT07075029 — RSV in Acute Respiratory Infection Surveillance Among Community-Dwelling Elderly Aged ≥50 Years in China · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT03898635 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Huashan Hospital
- Last refreshed: 2 April 2019
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03898635.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing